0000914475-24-000086.txt : 20240312 0000914475-24-000086.hdr.sgml : 20240312 20240312183857 ACCESSION NUMBER: 0000914475-24-000086 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240308 FILED AS OF DATE: 20240312 DATE AS OF CHANGE: 20240312 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Delaet Ingrid CENTRAL INDEX KEY: 0001965808 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 24743904 MAIL ADDRESS: STREET 1: C/O NEUROCRINE BIOSCIENCES, INC. STREET 2: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 wk-form4_1710283129.xml FORM 4 X0508 4 2024-03-08 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001965808 Delaet Ingrid 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Regulatory Officer 1 Common Stock 2024-03-08 4 M 0 1800 106.02 A 9307 D Common Stock 2024-03-08 4 S 0 1800 140.0292 D 7507 D Common Stock 2024-03-11 4 M 0 200 106.02 A 7707 D Common Stock 2024-03-11 4 S 0 200 140 D 7507 D Non-Qualified Stock Option 106.02 2024-03-08 4 M 0 1800 106.02 D 2031-02-01 Common Stock 1800 7567 D Non-Qualified Stock Option 106.02 2024-03-11 4 M 0 200 106.02 D 2031-02-01 Common Stock 200 7367 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.00 to $140.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Option granted February 1, 2021 and vests at 25% upon first anniversary (February 1, 2022) and remaining 75% vesting in 36 equal monthly installments beginning on March 1, 2022. /s/ Darin Lippoldt, Attorney-in-Fact 2024-03-12